Loading...

APC anti-mouse CD3 Antibody

Pricing & Availability
Clone
17A2 (See other available formats)
Regulatory Status
RUO
Other Names
T cell antigen receptor complex, T3
Isotype
Rat IgG2b, κ
Ave. Rating
Submit a Review
Product Citations
publications
17A2_APC_073012
C57BL/6 mouse splenocytes were stained with CD3 (clone 17A2) APC (filled histogram) or rat IgG2b, κ isotype control (open histogram).
  • 17A2_APC_073012
    C57BL/6 mouse splenocytes were stained with CD3 (clone 17A2) APC (filled histogram) or rat IgG2b, κ isotype control (open histogram).
Compare all formats See APC spectral data
Cat # Size Price Quantity Check Availability Save
100235 25 µg 27€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
100236 100 µg 62€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD3, also known as T3, is a member of the Ig superfamily and primarily expressed on T cells, NK-T cells, and at different levels on thymocytes during T cell differentiation. CD3 is composed of CD3ε, δ, γ and ζ chains. It forms a TCR complex by associating with TCR α/β or γ/δ chains. CD3 plays a critical role in TCR signal transduction, T cell activation, and antigen recognition by binding the peptide/MHC antigen complex

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
γδTCR-positive T-T hybridoma D1
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography and conjugated with APC under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤0.5 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Red Laser (633 nm)
Application Notes

Additional reported application (for relevant formats) include: spatial biology (IBEX)1,2.

Application References

(PubMed link indicates BioLegend citation)
  1. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
  2. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Koyama M, et al. 2015. J Exp Med. 212: 1303 - 1321. PubMed
  2. Morse M, et al. 2016. Lupus. 25: 81 - 87. PubMed
  3. Calabrese DR, et al. 2020. J Clin Invest. . PubMed
  4. Hou X, et al. 2020. Cell Reports. 28(1):172-189.e7.. PubMed
  5. Liu J, et al. 2019. Immunity. 50:600. PubMed
  6. Rivas MA, et al. 2021. Nat Immunol. 22:240. PubMed
  7. Xiang G, et al. 2022. Cell Death Dis. 13:451. PubMed
  8. Pani F, et al. 2021. Endocrinology. 162:. PubMed
  9. Hilfenhaus G, et al. 2021. Cancer Res. 81:619. PubMed
  10. Denny L, et al. 2021. Clin Transl Immunology. 10:e1234. PubMed
  11. Ramos SA, et al. 2022. J Allergy Clin Immunol. 149:767. PubMed
  12. Zhou Y, et al. 2021. Methods Mol Biol. 2388:35. PubMed
  13. Sugiura A, et al. 2022. Immunity. 55:65. PubMed
  14. Alam A, et al. 2022. Cancer Cell. 40:153. PubMed
  15. Cautivo KM, et al. 2022. Immunity. 55:254. PubMed
  16. Qi X, et al. 2022. FASEB J. 36:e22250. PubMed
  17. van Dierendonck XAMH, et al. 2022. Proc Natl Acad Sci U S A. 119:e2114739119. PubMed
  18. Corral D, et al. 2022. Cell Rep. 39:110715. PubMed
  19. Tu J, et al. 2022. Cancer Sci. 113:2496. PubMed
  20. Dolfi B, et al. 2022. Cell Rep. 39:110949. PubMed
  21. Du M, et al. 2022. Cancer Sci. 113:2974. PubMed
  22. Tessaro FHG, et al. 2022. Cell Rep. 39:110977. PubMed
  23. Grégoire C, et al. 2022. Immunity. 55:1216. PubMed
  24. Zhu J, et al. 2022. Research (Wash D C). 2022:9816272. PubMed
  25. Zhang Z, et al. 2022. Integr Cancer Ther. 21:15347354221138534. PubMed
  26. Miró L, et al. 2022. Cancers (Basel). 14: . PubMed
  27. An HW, et al. 2022. Cell Rep. 41:111878. PubMed
  28. Jin SM, et al. 2023. Nat Nanotechnol. :. PubMed
  29. Lin J, et al. 2023. Nat Commun. 14:224. PubMed
  30. Kang J, et al. 2023. JCI Insight. 8: . PubMed
  31. Chen Y, et al. 2023. Stem Cells Int. 2023:7482546. PubMed
  32. Li X, et al. 2022. Cell. 185:1709. PubMed
  33. Bergmann CA, et al. 2022. Cells. 11:. PubMed
  34. Akhtar MN, et al. 2022. MBio. 13:e0330921. PubMed
  35. Balakrishnan PB, et al. 2022. Nano Res. 15:2300. PubMed
  36. Shi X, et al. 2022. Proc Natl Acad Sci U S A. 119:e2208506119. PubMed
  37. Ho HM, et al. 2022. Pharmaceutics. 14:. PubMed
  38. Sparbier CE, et al. 2023. Nat Cell Biol. 25:258. PubMed
  39. Pan Y, et al. 2023. Adv Sci (Weinh). 10:e2206792. PubMed
  40. Wang X, et al. 2023. J Immunother Cancer. 11:. PubMed
  41. Liu N, et al. 2023. Cell Death Dis. 14:170. PubMed
  42. Gupta T, et al. 2023. Front Immunol. 14:1044703. PubMed
  43. Mabire M, et al. 2023. Nat Commun. 14:1830. PubMed
  44. Fu S, et al. 2023. Nat Commun. 14:2248. PubMed
  45. Li T, et al. 2023. Nat Commun. 14:2498. PubMed
  46. Zhang Z, et al. 2023. Aging Dis. 14:966. PubMed
  47. Bhaskar A, et al. 2023. iScience. 26:106644. PubMed
  48. Changsheng H, et al. 2023. Sci Adv. 9:eade4186. PubMed
  49. Cansever D, et al. 2023. Nat Immunol. . PubMed
  50. Naito Y, et al. 2019. American Journal of Physiology-Renal Physiology. 318(1):F238-F247. PubMed
  51. Yang H, et al. 2019. Mol Metab. 23:24. PubMed
  52. Gabriely G, et al. 2021. iScience. 24:103347. PubMed
  53. Delvecchio FR, et al. 2021. Cell Mol Gastroenterol Hepatol. 12:1543. PubMed
  54. Kim D, et al. 2021. Nanomicro Lett. 13:31. PubMed
  55. Sano T, et al. 2021. Cell Reports. 36:109608. PubMed
  56. Wilson RP, et al. 2019. PLoS Pathog. 15:e1007745. PubMed
  57. Yu VWC et al. 2016. Cell. 167(5):1310-1322 . PubMed
  58. Huang X, et al. 2019. Cancer Immunol Res. 1.388888889. PubMed
  59. Gupta SS, et al. 2019. Cell Rep. 29:1862. PubMed
  60. Fu X, et al. 2020. J Immunol. 205:2066. PubMed
  61. Song J, et al. 2021. J Am Heart Assoc. 10:e017329. PubMed
  62. Baram T, et al. 2021. Cells. 10:. PubMed
  63. Luo R, et al. 2021. Theranostics. 11:117. PubMed
  64. Pessoa Rodrigues C, et al. 2021. Sci Adv. 7:. PubMed
  65. Zhang S, et al. 2022. Cell Death Dis. 13:844. PubMed
  66. Forte E, et al. 2020. J Cell Mol Med. . PubMed
  67. Haque M, et al. 2021. STAR Protoc. 2:100264. PubMed
  68. Gruber T, et al. 2020. JCI Insight. 5:00. PubMed
  69. Yamamoto R et al. 2018. Cell stem cell. 22(4):600-607 . PubMed
  70. Greenberg J, et al. 2022. JCI Insight. Online ahead of print. PubMed
  71. Kremenovic M, et al. 2022. J Immunother Cancer. 10:. PubMed
  72. Peng Z, et al. 2021. STAR Protocols. 2(2):100595. PubMed
  73. Wang X, et al. 2021. Front Cell Dev Biol. 632805:9. PubMed
  74. Swidergall M, et al. 2019. Cell Rep. 28:423. PubMed
  75. Tsuchiya N, et al. 2020. Cell Reports. 29(1):162-175.e9.. PubMed
  76. Fujino T, et al. 2021. Nat Commun. 12:1826. PubMed
  77. Shi S, et al. 2020. Clin Cancer Res. 26:5990. PubMed
  78. Almutairi F, et al. 2021. Front Immunol. 12:772288. PubMed
  79. Magod P, et al. 2021. Cell Reports. 36(5):109480. PubMed
  80. Yoshimi A, et al. 2019. Nature. 574:273. PubMed
  81. Thomas S, et al. 2019. J Immunother Cancer. 7:214. PubMed
  82. Uchimura T et al. 2018. Immunity. 49(6):1049-1061 . PubMed
  83. Zhang X, et al. 2022. Pharmaceutics. 14:. PubMed
  84. Tang D, et al. 2020. Br J Haematol. 191:906. PubMed
  85. van Elsas MJ, et al. 2022. Int J Mol Sci. 23:. PubMed
  86. Francian A, et al. 2021. J Drug Target. 29:754. PubMed
  87. Antunes KH, et al. 2022. Front Immunol. 13:867022. PubMed
  88. Mastandrea I, et al. 2022. STAR Protoc. 3:101106. PubMed
  89. Wu G, et al. 2020. Br J Pharmacol. 177:5063. PubMed
  90. Zhang Z, et al. 2021. Oncoimmunology. 10:1912472. PubMed
  91. Parada-Kusz M, et al. 2018. Dis Model Mech. 11:. PubMed
  92. Zhang F, et al. 2019. Immunity. 50:738. PubMed
  93. Liu H, et al. 2020. Cancer Cell. 37(3):324-339. PubMed
  94. Li X, et al. 2020. Mol Ther. 28:2430. PubMed
  95. Guo W, et al. 2022. J Immunother Cancer. 10:. PubMed
  96. Ren HZ, et al. 2022. J Clin Transl Hepatol. 10:1138. PubMed
  97. Utley A, et al. 2020. Cell Rep. 31:107815. PubMed
  98. Utz B, et al. 2020. Sci Rep. 10:18733. PubMed
  99. Hiramoto T, et al. 2018. Mol Ther. 26:1255. PubMed
  100. Yu VWC, et al. 2017. Cell. 168:944. PubMed
  101. Wang GZ, et al. 2019. Nat Commun. 10:1125. PubMed
  102. Chen X et al. 2017. Cell stem cell. 21(6):747-760 . PubMed
  103. Wang W, et al. 2022. Aging Cell. 21:e13630. PubMed
  104. Xie Z, et al. 2020. Light Sci Appl. 0.486805556. PubMed
  105. Court AC, et al. 2020. EMBO Rep. 21:e48052. PubMed
  106. Venturutti L, et al. 2020. Cell. 182(2):297-316.e27. PubMed
  107. Zhang W, et al. 2019. Oncol Lett. 17:815. PubMed
  108. Schadt L, et al. 2020. Cell Reports. 29(5):1236-1248.e7.. PubMed
  109. Hu Q, et al. 2018. Nat Biomed Eng. 0.660416667. PubMed
  110. Suryawanshi RK, et al. 2021. Nat Commun. 12:6020. PubMed
  111. Du Y, et al. 2022. Nat Commun. 13:231. PubMed
  112. Chauveau A, et al. 2020. Immunity. 52:794. PubMed
  113. Haikala HM, et al. 2019. Nat Commun. 10:620. PubMed
  114. Zhao X, et al. 2022. Nat Protoc. 17:2240. PubMed
  115. Zuo W, et al. 2022. Cell Death Discov. 8:257. PubMed
  116. Reinfeld BI, et al. 2021. Nature. 593:282. PubMed
  117. Kruta M, et al. 2021. Cell Stem Cell. :. PubMed
  118. Liu Y, et al. 2017. Oncogene. 10.1038/onc.2017.209. PubMed
  119. Hu J, et al. 2019. Mol Ther Nucleic Acids. 16:650. PubMed
  120. Burr ML, et al. 2019. Cancer Cell. 36:385. PubMed
  121. Liang J, et al. 2020. Sci Adv. 6:eabc3646. PubMed
  122. Huang Z, et al. 2021. Nat Commun. 12:145. PubMed
  123. Zhu Y, et al. 2021. EMBO J. 40:e105320. PubMed
  124. Wang Y, et al. 2021. Front Microbiol. 12:701566. PubMed
  125. Zheng D, et al. 2022. Acta Pharm Sin B. 12:2740. PubMed
  126. Tomala J, et al. 2020. Methods Mol Biol. 2111:101. PubMed
  127. Wen M, et al. 2022. JCI Insight. Online ahead of print. PubMed
  128. Stirling ER, et al. 2022. J Immunother Cancer. 10:. PubMed
  129. Li H, et al. 2021. Adv Sci (Weinh). 2001596:8. PubMed
  130. Tomay F, et al. 2019. J Transl Med. 17:237. PubMed
  131. Xiong W, et al. 2022. Adv Sci (Weinh). 9:e2103029. PubMed
  132. Xiao L, et al. 2021. Clin Cancer Res. 27:4338. PubMed
  133. Huang L, et al. 2021. Breast Cancer Res Treat. Online ahead of print. PubMed
  134. Han F, et al. 2020. Invest Ophthalmol Vis Sci. 61:24. PubMed
  135. Wang X, et al. 2020. Nat Commun. 4.505555556. PubMed
  136. Johnson DC, et al. 2020. Cell Death Dis. 0.894444444. PubMed
  137. Evgin L, et al. 2020. Nat Commun. 2.671527778. PubMed
  138. Wei Z, et al. 2021. Nat Commun. 0.805555556. PubMed
  139. Xu P, et al. 2020. Cancer Immunol Res. 8:1193. PubMed
  140. Xi‐Zhi J Guo et al. 2018. Immunity. 49(3):531-544 . PubMed
  141. Subramanian K, et al. 2019. Nat Microbiol. 4:62. PubMed
  142. Yu H, et al. 2021. Front Oncol. 11:736882. PubMed
  143. Chen C, et al. 2021. J Virol. 95:e0082921. PubMed
  144. Martinez-Turtos A, et al. 2022. Oncoimmunology. 11:2116844. PubMed
  145. Zeng Q, et al. 2022. iScience. 25:105151. PubMed
  146. Adnan-Awad S, et al. 2020. Leukemia. . PubMed
  147. Liu Y, et al. 2020. Oncol Lett. 2369:20. PubMed
  148. Chen R, et al. 2021. Cell Reports. 34(7):108751. PubMed
  149. Cianciaruso C, et al. 2020. Cell Reports. 27(10):3062-3080.e11.. PubMed
  150. Zhang J, et al. 2018. Nature. 553:91. PubMed
  151. Pascual-Pasto G, et al. 2022. J Immunother Cancer. 10:. PubMed
  152. Li Z, et al. 2022. Nat Commun. 13:6321. PubMed
  153. Olivo Pimentel V, et al. 2021. J Immunother Cancer. 9:. PubMed
  154. Li M, et al. 2021. Cancers (Basel). 13:. PubMed
  155. Jiang L, et al. 2020. Cell. 183(5):1219-1233.e18. PubMed
  156. Yu M, et al. 2021. Molecular Cell. 81(6):1216-1230.e9. PubMed
  157. Liu P, et al. 2020. Mol Cell. 748:77. PubMed
  158. Nechama M, et al. 2018. Nat Commun. 9:1603. PubMed
  159. Liu YG, et al. 2019. FASEB J. 33:5018. PubMed
  160. Siddique SM, et al. 2019. Sci Rep. 9:13977. PubMed
  161. Kim S, et al. 2020. Autophagy. :1. PubMed
  162. Lazarian G, et al. 2021. Cancer Cell. 39(3):380-393.e8. PubMed
  163. Clemente–Casares X, et al. 2017. Immunity. 47:974. PubMed
  164. Olson CA, et al. 2021. Cell Host Microbe. 29:1378. PubMed
  165. Li K, et al. 2020. Nat Commun. 4.844444444. PubMed
  166. Hering L, et al. 2020. Front Immunol. 1.747222222. PubMed
  167. Yoshida S, et al. 2022. PLoS One. 17:e0264317. PubMed
  168. Zhong C, et al. 2021. J Virol. 95:e0092521. PubMed
  169. Kelley WJ, et al. 2022. JCI Insight. 7: . PubMed
  170. Wang Y, et al. 2021. Cell Reports. 36(6):109516. PubMed
  171. Hidalgo San Jose L, et al. 2020. Cell Rep. 30:69. PubMed
  172. Hao L, et al. 2021. Br J Pharmacol. 178:4726. PubMed
  173. Lau P, et al. 2022. Cell Mol Immunol. :. PubMed
  174. Arora S, et al. 2021. Med (N Y). 2:938. PubMed
  175. Li H, et al. 2022. iScience. 25:104481. PubMed
  176. Gardenier J, et al. 2017. Nat Commun. 8:14345. PubMed
  177. Heyde A, et al. 2021. Cell. 184(5):1348-1361.e22. PubMed
  178. Zeng A, et al. 2020. Oncol Rep. . PubMed
  179. Das A, et al. 2020. J Bone Miner Res. 36:199. PubMed
  180. Agelidis A, et al. 2017. Cell Rep. 10.1016/j.celrep.2017.06.041. PubMed
  181. Sartorius R, et al. 2018. Front Immunol. 1.413888889. PubMed
  182. Hong Y, et al. 2019. J Extracell Vesicles. 8:1670893. PubMed
  183. Lightman SM, et al. 2020. Cell Reports. 1.086805556. PubMed
  184. Kujur W, et al. 2020. PLoS Pathog. 16:e1009132. PubMed
  185. Wang X, et al. 2021. Sci Transl Med. 13:. PubMed
  186. Rappe JCF, et al. 2021. J Exp Med. 218:. PubMed
  187. Lee A, et al. 2022. Nat Commun. 13:549. PubMed
  188. Tripathi D, et al. 2016. Nat Commun. 7:13896. PubMed
  189. Pessoa Rodrigues C, et al. 2020. Sci Adv. 6:eaaz4815. PubMed
  190. Song X, et al. 2022. Transl Oncol. 15:101306. PubMed
  191. Akhtar MN, et al. 2020. PLoS Pathog. 16:e1009136. PubMed
  192. Zhang J, et al. 2021. Stem Cell Res Ther. 12:579. PubMed
  193. Chang MH, et al. 2021. Cell Rep. 37:109902. PubMed
  194. Xie Z, et al. 2020. Light Sci Appl. 9:161. PubMed
  195. Lake CM, et al. 2021. Cell Death Dis. 12:400. PubMed
RRID
AB_2561455 (BioLegend Cat. No. 100235)
AB_2561455 (BioLegend Cat. No. 100236)

Antigen Details

Structure
Ig superfamily, CD3/TCR, 20 kD
Distribution

Thymocytes (differentiation dependent), mature T cells, NK-T cells

Function
Antigen recognition, TCR signal transduction, T cell activation
Ligand/Receptor
Peptide antigen/MHC-complex
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Davis MM. 1990. Annu. Rev. Biochem. 59:475.
3. Weiss A, et al. 1994. Cell 76:263.

Gene ID
12502 View all products for this Gene ID
UniProt
View information about CD3 on UniProt.org

Other Formats

View All CD3 Reagents Request Custom Conjugation
Description Clone Applications
FITC anti-mouse CD3 17A2 FC
PE anti-mouse CD3 17A2 FC
Purified anti-mouse CD3 17A2 FC,IHC-F,IP,ICC
Alexa Fluor® 647 anti-mouse CD3 17A2 FC,IHC-F,3D IHC,SB
Alexa Fluor® 488 anti-mouse CD3 17A2 FC,IHC-F,3D IHC
Pacific Blue™ anti-mouse CD3 17A2 FC
Alexa Fluor® 700 anti-mouse CD3 17A2 FC
PerCP/Cyanine5.5 anti-mouse CD3 17A2 FC
PE/Cyanine7 anti-mouse CD3 17A2 FC
APC/Cyanine7 anti-mouse CD3 17A2 FC
Brilliant Violet 421™ anti-mouse CD3 17A2 FC,ICC
Brilliant Violet 570™ anti-mouse CD3 17A2 FC
Brilliant Violet 650™ anti-mouse CD3 17A2 FC
Brilliant Violet 785™ anti-mouse CD3 17A2 FC
Brilliant Violet 510™ anti-mouse CD3 17A2 FC
APC anti-mouse CD3 17A2 FC
Ultra-LEAF™ Purified anti-mouse CD3 17A2 FC,IHC-F,IP,ICC
Brilliant Violet 605™ anti-mouse CD3 17A2 FC
Alexa Fluor® 594 anti-mouse CD3 17A2 IHC-F,FC,3D IHC,SB
Brilliant Violet 711™ anti-mouse CD3 17A2 FC
Biotin anti-mouse CD3 17A2 FC,IHC-F
PE/Dazzle™ 594 anti-mouse CD3 17A2 FC
APC/Fire™ 750 anti-mouse CD3 17A2 FC
Brilliant Violet 750™ anti-mouse CD3 17A2 FC
TotalSeq™-A0182 anti-mouse CD3 17A2 PG
TotalSeq™-B0182 anti-mouse CD3 17A2 PG
Spark Blue™ 550 anti-mouse CD3 17A2 FC
Spark NIR™ 685 anti-mouse CD3 17A2 FC
TotalSeq™-C0182 anti-mouse CD3 17A2 PG
APC/Fire™ 810 anti-mouse CD3 17A2 FC
PE/Fire™ 640 anti-mouse CD3 17A2 FC
Spark YG™ 570 anti-mouse CD3 17A2 IHC-F
PE/Fire™ 700 anti-mouse CD3 17A2 FC
PE/Cyanine5 anti-mouse CD3 17A2 FC
Spark Blue™ 574 anti-mouse CD3 Antibody 17A2 FC
Spark Violet™ 423 anti-mouse CD3 17A2 FC
PE/Fire™ 810 anti-mouse CD3 17A2 FC
Spark Red™ 718 anti-mouse CD3 17A2 FC
Spark UV™ 387 anti-mouse CD3 17A2 FC
Go To Top Version: 1    Revision Date: 11/30/2012

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account